Extrapyramidal symptoms (EPS) are involuntary movement problems caused by medications that block dopamine activity in the brain. They range from sudden muscle spasms to a persistent, uncomfortable restlessness to slow, repetitive movements of the face and limbs. Antipsychotic medications are the most common cause, but certain anti-nausea drugs can trigger them too.
Why These Symptoms Happen
Your brain has a movement-control network called the basal ganglia that relies on dopamine to keep muscles coordinated and smooth. Medications that block dopamine receptors in this area, particularly a specific type called D2 receptors, disrupt that signaling. When roughly 75% or more of these receptors are blocked, the risk of extrapyramidal symptoms rises sharply. Older antipsychotics like haloperidol tend to occupy a high percentage of these receptors, which is why they carry a much greater risk than newer alternatives.
It’s not only psychiatric medications that cause the problem. Anti-nausea drugs such as metoclopramide and prochlorperazine also block dopamine receptors, and their extrapyramidal side effects can be mistaken for anxiety, depression, or even catatonia. This overlap sometimes delays the correct diagnosis.
The Four Main Types
EPS isn’t a single symptom. It’s an umbrella term for four distinct movement disorders, each with its own timeline and pattern.
Acute Dystonia
Acute dystonia is the fastest to appear, often developing within minutes to hours of starting a new medication or increasing a dose. Muscles contract involuntarily and lock into abnormal positions. The neck, jaw, tongue, and eye muscles are most commonly affected. You might see the head tilt backward, the eyes fix in one direction (a phenomenon called oculogyric crisis), or the jaw clench shut. These episodes are painful and frightening, and when the muscles of the throat are involved, breathing can become compromised, producing a high-pitched sound with each breath.
Akathisia
Akathisia is one of the most distressing extrapyramidal symptoms because it has both a mental and physical component. People describe an intense inner restlessness, a feeling that they simply cannot sit still, particularly in their legs. Outwardly, this shows up as constant pacing, rocking back and forth, shifting weight from one foot to the other, or crossing and uncrossing the legs. The movement is repetitive and hard to suppress. Because the distress it causes can look like agitation or worsening of the psychiatric condition being treated, akathisia is frequently misidentified, which can lead to dose increases that make the problem worse.
Drug-Induced Parkinsonism
This form of EPS closely mimics Parkinson’s disease, producing tremor, muscle stiffness, slowed movement, and difficulty walking. A few features help distinguish it from actual Parkinson’s: drug-induced parkinsonism tends to develop more quickly, affects both sides of the body equally, and is less likely to include the classic resting tremor. It may also be accompanied by repetitive, involuntary chewing or lip-smacking movements. Symptoms typically emerge within weeks of starting or increasing the medication.
Tardive Dyskinesia
Tardive dyskinesia is the delayed form of EPS. It develops after months or years of treatment, making it both the slowest to appear and the hardest to reverse. The hallmark is repetitive, involuntary movements of the face, especially lip smacking, tongue darting, and grimacing, though the arms, legs, and trunk can be affected too.
At least 20% of patients treated long-term with older antipsychotics develop tardive dyskinesia. Newer antipsychotics carry a lower but still real risk, with an annualized incidence of about 3.9% compared to 5.5% for older drugs. Certain groups face higher odds: women (especially after menopause, with incidence rates reaching 30% within roughly a year of exposure), older adults, and African Americans on long-term dopamine-blocking medications. Estrogen may have a protective effect, which could explain the sharp increase in risk after menopause. Using anticholinergic medications for extended periods, paradoxically often prescribed to manage other forms of EPS, can also increase the risk of tardive dyskinesia.
Even after stopping the medication, tardive dyskinesia persists in 10% to 30% of patients.
Which Medications Carry the Highest Risk
The risk of EPS varies enormously depending on which drug you’re taking. Older (first-generation) antipsychotics cause movement disorders in an estimated 50% to 75% of patients on long-term treatment. That’s a strikingly high number. Newer (second-generation) antipsychotics like quetiapine, olanzapine, and risperidone have a substantially lower likelihood, though they are not risk-free. Of the newer drugs, risperidone tends to produce more EPS at higher doses because it still binds tightly to D2 receptors.
Outside of psychiatry, the anti-nausea medications metoclopramide and prochlorperazine are the most common culprits. Because these are sometimes prescribed casually for nausea or acid reflux, patients and even some clinicians may not connect the movement symptoms to the medication.
How EPS Is Identified
Clinicians use a structured assessment called the Abnormal Involuntary Movement Scale (AIMS) to screen for tardive dyskinesia specifically. During the exam, you’ll be asked to sit with your hands on your knees, let your hands hang unsupported, open your mouth and stick out your tongue, tap your fingers rapidly, extend your arms, stand up, and walk a few paces. The examiner watches for involuntary movements in the face, limbs, and trunk throughout. Each body area is rated on a 0-to-4 scale, from none to severe, and a total score is calculated. This screening is recommended at regular intervals for anyone on long-term antipsychotic therapy.
For akathisia and drug-induced parkinsonism, diagnosis relies more on clinical observation and the patient’s own description of their experience. The timing of symptom onset relative to medication changes is often the strongest clue.
How EPS Is Treated
Treatment depends on which type of EPS you’re dealing with. Acute dystonia is treated as an urgent problem. An injection of an anticholinergic medication typically resolves the muscle spasms within 20 to 30 minutes. If the first dose doesn’t fully work, a second can be given after half an hour. Once the acute episode is resolved, an oral medication is usually continued for a period to prevent recurrence.
For drug-induced parkinsonism, an oral anticholinergic may be started at a low dose and gradually increased over five to six days until symptoms improve without causing too many side effects. The most common approach is to find the lowest effective maintenance dose.
Akathisia often responds poorly to anticholinergics alone. Reducing the dose of the offending medication, switching to a drug with lower D2 receptor binding, or adding a beta-blocker or benzodiazepine are strategies that may help.
Tardive dyskinesia has historically been the most difficult form to treat. In 2017, the FDA approved the first medication specifically designed for tardive dyskinesia in adults. It works by reducing the amount of dopamine packaged and released by nerve cells, rather than blocking the receptor itself. Clinical trials showed meaningful reductions in involuntary movements, the benefits were sustained over 42 weeks of follow-up, and no life-threatening side effects were reported. This was a significant shift for a condition that previously had no approved treatment.
Older vs. Newer Antipsychotics and Risk
If you’re taking an antipsychotic and concerned about EPS, the type of drug matters. A large meta-analysis found that patients on first-generation antipsychotics develop movement disorders at dramatically higher rates than those on second-generation drugs. But “second-generation” is not a guarantee of safety. Among the newer drugs, the degree of D2 receptor blockade varies. Risperidone at higher doses behaves more like an older antipsychotic in terms of EPS risk, while quetiapine and clozapine sit at the lower end of the risk spectrum.
The duration of treatment also matters independently of which drug is used. Longer exposure increases the risk of tardive dyskinesia in particular, which is why regular movement screenings are a standard part of long-term antipsychotic care.